Lopinavir (Synonyms: A157378.0, ABT378)

Cell lines

MT4 cells

Preparation method

The solubility of this compound in DMSO is > 31.5 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

4 ~ 52 nM

Applications

HIV with multiple mutations was markedly less resistant to Lopinavir than to Ritonavir. Although the activity of Lopinavir declined significantly against the multiply mutated strains compared with its activity against the baseline strains, the extent of the decline was substantially less than that of Ritonavir. Furthermore, the EC50 value of Lopinavir against HIV with multiple mutations was 10-fold lower than that of Ritonavir.

Animal models

Rats

Dosage form

10 mg/kg; p.o.

Applications

The Cmax and oral bioavailability of Lopinavir in rats were 0.8 μg/mL and 25%, respectively. At 6th hr, the plasma level of Lopinavir declined below the level of quantitation (0.01 μg/mL). However, co-administration of Lopinavir with Ritonavir (10 mg/kg) maintained the concentrations of Lopinavir in excess of 3 μg/mL with low variability. In addition, the area under the plasma concentration-time curve from 0 ~ 8 hrs for Lopinavir increased 14-fold due to Ritonavir co-administration.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ, Norbeck DW. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998 Dec;42(12):3218-24.